Detailed Narrative
JB Pharma Acquisition: A Strategic Pivot
Torrent has successfully acquired a 48.8% controlling stake in JB Pharma, with consolidation set to begin from January 21st. Management has identified significant cost synergies of ₹400-450 crores to be realized over the next 2-3 years, with 20% expected in the first year. While Q4 FY26 might see some integration-related softness, the long-term goal is to bring JB's 28-29% EBITDA margins closer to Torrent's base business margin of ~33%.
India Business Continues to Outpace Market
The India business grew 14% YoY to ₹1,798 crores, significantly ahead of the IPM's 10% growth. This outperformance was driven by a 5.5% volume growth and strong traction in chronic segments like Cardiac, Gastro, and Diabetes. The Curatio acquisition continues to yield results with 27% growth, supported by increased OTC ad spends and field force expansion, which is on track to exceed 7,000 members by year-end.
International Markets: Brazil Strength vs Germany Headwinds
Brazil remains a high-growth engine with 10% constant currency growth and 13% secondary sales growth. However, Germany faced a 6% CC decline due to persistent supply disruptions at a third-party manufacturer, a situation that may take 3-4 quarters to resolve via alternate sourcing. In the US, revenue grew 12% in CC terms to $36 million, with management targeting a $200 million annual run rate by FY27 through 5-7 new launches per year.
GLP-1 Opportunity and Regulatory Hurdles
Torrent is positioning itself for the massive GLP-1 opportunity in Brazil, having filed for Ozempic generics. While ANVISA is prioritizing these filings, the launch is now expected in the next financial year. Management conservatively expects 45-50% price erosion in this market but sees it as a significant volume opportunity. In India, the company plans to partner for injectable GLP-1s while maintaining internal capacity for oral formulations.
Financial Health and Deleveraging Roadmap
Despite the JB acquisition, Torrent maintains a manageable net debt of ₹880 crores as of December. Management provided a clear deleveraging path, targeting a Net Debt to EBITDA ratio of 1-1.1x by FY28 and further reduction to 0.6x by FY29. The average cost of interest remains stable at approximately 7.6%, and the company continues to generate strong operating cash flows to support its growth initiatives.